Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Other Non Operating Income: 2010-2025

Historic Other Non Operating Income for Altimmune (ALT) over the last 16 years, with Sep 2025 value amounting to -$86,000.

  • Altimmune's Other Non Operating Income fell 577.78% to -$86,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$45,000, marking a year-over-year increase of 10.00%. This contributed to the annual value of $48,000 for FY2024, which is 71.08% down from last year.
  • Altimmune's Other Non Operating Income amounted to -$86,000 in Q3 2025, which was up 6.52% from -$92,000 recorded in Q2 2025.
  • Altimmune's Other Non Operating Income's 5-year high stood at $118,000 during Q4 2024, with a 5-year trough of -$286,000 in Q3 2021.
  • Over the past 3 years, Altimmune's median Other Non Operating Income value was $15,000 (recorded in 2025), while the average stood at $4,636.
  • The largest annual percentage gain for Altimmune's Other Non Operating Income in the last 5 years was 542.33% (2021), contrasted with its biggest fall of 1,078.85% (2021).
  • Altimmune's Other Non Operating Income (Quarterly) stood at -$81,000 in 2021, then crashed by 167.90% to -$217,000 in 2022, then skyrocketed by 109.22% to $20,000 in 2023, then soared by 490.00% to $118,000 in 2024, then tumbled by 577.78% to -$86,000 in 2025.
  • Its Other Non Operating Income stands at -$86,000 for Q3 2025, versus -$92,000 for Q2 2025 and $15,000 for Q1 2025.